BioRestorative Therapies, Inc. Common Stock (NV) (BRTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BRTX trades at $0.17 with a market cap of $4.75M and a P/E ratio of -0.11. BRTX moved -7.84% today. Year to date, BRTX is -85.80%; over the trailing twelve months it is -89.15%. Its 52-week range spans $0.16 to $2.55. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces BRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioRestorative Therapies Unveils MSC Exosome Proteomics from Cord, Adipose, Bone Marrow Enabling Targeted Regenerative, Aesthetic Applications: Preclinical proteomic analyses reveal that extracellular vesicles from umbilical cord, brown adipose tissue and bone marrow mesenchymal stem cells exhibit distinct protein signatures tied to regenerative signaling, immune modulation and epidermal barrier formation. These insights underpin development of targeted EV-based formulations for skin rejuvenation, scar repair, post-procedural recovery and hair health.
| Metric | Value |
|---|---|
| Price | $0.17 |
| Market Cap | $4.75M |
| P/E Ratio | -0.11 |
| EPS | $-1.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.55 |
| 52-Week Low | $0.16 |
| Volume | 93.57K |
| Avg Volume | 0 |
| Revenue (TTM) | $359.70K |
| Net Income | $-14.24M |
| Gross Margin | 93.37% |
2 analysts cover BRTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.